Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C.

Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee WM, Lok AS, Di Bisceglie AM, Bonkovsky HL, Hoefs JC, Dienstag JL, Morishima C, Abnet CC, Sinha R; HALT-C Trial Group.

Hepatology. 2009 Nov;50(5):1360-9. doi: 10.1002/hep.23162.

2.

Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C.

Freedman ND, Curto TM, Lindsay KL, Wright EC, Sinha R, Everhart JE; HALT-C TRIAL GROUP.

Gastroenterology. 2011 Jun;140(7):1961-9. doi: 10.1053/j.gastro.2011.02.061. Epub 2011 Mar 2.

3.

Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.

Papastergiou V, Stampori M, Lisgos P, Pselas C, Prodromidou K, Karatapanis S.

Eur J Gastroenterol Hepatol. 2013 Jul;25(7):798-805. doi: 10.1097/MEG.0b013e32835eb8bf.

PMID:
23395996
4.

Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.

Lok AS, Everhart JE, Chung RT, Kim HY, Everson GT, Hoefs JC, Greenson JK, Sterling RK, Lindsay KL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Ghany MG, Morishima C; HALT-C Trial Group.

Hepatology. 2009 Jun;49(6):1828-37. doi: 10.1002/hep.22865.

5.

Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.

Morishima C, Shiffman ML, Dienstag JL, Lindsay KL, Szabo G, Everson GT, Lok AS, Di Bisceglie AM, Ghany MG, Naishadham D, Morgan TR, Wright EC; HALT-C Trial Group.

Am J Gastroenterol. 2012 Sep;107(9):1388-98. doi: 10.1038/ajg.2012.137. Epub 2012 Jun 12.

6.

Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.

Soresi M, Tripi S, Franco V, Giannitrapani L, Alessandri A, Rappa F, Vuturo O, Montalto G.

Liver Int. 2006 Nov;26(9):1119-25.

PMID:
17032413
7.

Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.

Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL; HALT-C Trial Investigators.

N Engl J Med. 2008 Dec 4;359(23):2429-41. doi: 10.1056/NEJMoa0707615.

8.

Nitazoxanide for chronic hepatitis C.

Nikolova K, Gluud C, Grevstad B, Jakobsen JC.

Cochrane Database Syst Rev. 2014 Apr 6;(4):CD009182. doi: 10.1002/14651858.CD009182.pub2. Review.

PMID:
24706397
9.

Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.

Hauser G, Awad T, Brok J, Thorlund K, Štimac D, Mabrouk M, Gluud C, Gluud LL.

Cochrane Database Syst Rev. 2014 Feb 28;(2):CD005441. Review.

PMID:
24585509
10.

Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.

Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok AS, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C; HALT-C Trial Group.

Hepatology. 2006 Dec;44(6):1675-84.

11.

A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C.

Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C, Stoddard AM, Everhart JE; HALT-C Trial Group.

Hepatology. 2011 Aug;54(2):396-405. doi: 10.1002/hep.24370. Epub 2011 Jun 23.

12.

Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial.

Hoefs JC, Shiffman ML, Goodman ZD, Kleiner DE, Dienstag JL, Stoddard AM; HALT-C Trial Group.

Gastroenterology. 2011 Sep;141(3):900-908.e1-2. doi: 10.1053/j.gastro.2011.06.007. Epub 2011 Jun 12.

13.

Aminoadamantanes for chronic hepatitis C.

Lamers MH, Broekman M, Drenth JP, Gluud C.

Cochrane Database Syst Rev. 2014 May 3;(5):CD010125. doi: 10.1002/14651858.CD010125.pub2. Review.

PMID:
24793264
14.

Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.

Sagnelli E, Pisaturo M, Stanzione M, Messina V, Alessio L, Sagnelli C, Starace M, Pasquale G, Coppola N.

Clin Gastroenterol Hepatol. 2013 Sep;11(9):1174-1180.e11. doi: 10.1016/j.cgh.2013.03.025. Epub 2013 Apr 13.

PMID:
23591280
15.

Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial.

Ghany MG, Kim HY, Stoddard A, Wright EC, Seeff LB, Lok AS; HALT-C Trial Group.

Hepatology. 2011 Nov;54(5):1527-37. doi: 10.1002/hep.24550.

16.

Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection.

von Wagner M, Hofmann WP, Teuber G, Berg T, Goeser T, Spengler U, Hinrichsen H, Weidenbach H, Gerken G, Manns M, Buggisch P, Herrmann E, Zeuzem S.

Hepatology. 2008 Nov;48(5):1404-11. doi: 10.1002/hep.22483.

PMID:
18846541
17.
18.

Factors associated with early virological response to peginterferon-α-2a/ribavirin in chronic hepatitis C.

García-Samaniego J, Romero M, Granados R, Alemán R, Jorge Juan M, Suárez D, Pérez R, Castellano G, González-Portela C.

World J Gastroenterol. 2013 Mar 28;19(12):1943-52. doi: 10.3748/wjg.v19.i12.1943.

19.

Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.

Liang CC, Liu CH, Chung CS, Lin CK, Su TH, Yang HC, Liu CJ, Chen PJ, Chen DS, Kao JH.

J Infect Dis. 2015 May 1;211(9):1429-36. doi: 10.1093/infdis/jiu630. Epub 2014 Nov 11.

PMID:
25387585
20.

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, Corpas R, Cruz M, Grande L, Vázquez L, Muñoz-De-Rueda P, López-Serrano P, Gila A, Gutiérrez ML, Pérez C, Ruiz-Extremera A, Suárez E, Castillo J.

Gastroenterology. 2005 Mar;128(3):636-41.

PMID:
15765399

Supplemental Content

Support Center